| “Swimming in resistance”: co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa D Marchaim, F Perez, J Lee, S Bheemreddy, AM Hujer, S Rudin, ... American journal of infection control 40 (9), 830-835, 2012 | 80 | 2012 |
| 1083. Risk Factors Associated with Treatment of Asymptomatic Bacteriuria in the Emergency Department: A Multi-Hospital Cohort Study LA Petty, VM Vaughn, TS Patel, AN Malani, JM Pogue, L Dumkow, ... Open Forum Infectious Diseases 6 (Supplement_2), S384-S385, 2019 | | 2019 |
| 1106. Assessment of Fluoroquinolone Appropriateness for Hospitalized Patients with Asymptomatic Bacteriuria and Cystitis: A Multi-Hospital Cohort Study TN Gandhi, LA Petty, VM Vaughn, TS Patel, D Ratz, E McLaughlin, ... Open Forum Infectious Diseases 6 (Supplement_2), S393-S394, 2019 | | 2019 |
| 1117. Tazobactam Pharmacokinetic/Pharmacodynamic Target Attainment in Healthy Volunteers and Critically-Ill Hospitalized Patients SN Kalaria, JM Pogue, E Heil, E Heil Open Forum Infectious Diseases 8 (Supplement_1), S651-S651, 2021 | | 2021 |
| 1185. Impact of Utilizing Drug Resistance in Pneumonia (DRIP) Score on Management of Pneumonia A Sandhu, E Goldman, J Polistico, S Polistico, A Oudeif, A Aranha, ... Open Forum Infectious Diseases 6 (Supplement_2), S425-S425, 2019 | | 2019 |
| 1223: Breadth of Antibiotic Exposure and Likelihood of Inpatient Mortality in Sepsis J Smith, R Manickam, F Barreda, J Greene, M Bhimarao, J Pogue, ... Critical Care Medicine 49 (1), 615, 2021 | | 2021 |
| 1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA … NJ Onufrak, SM Bhavnani, JM Pogue, CM Rubino Open Forum Infectious Diseases 5 (Suppl 1), S437, 2018 | | 2018 |
| 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia O Albin, O Henig, TS Patel, JM Pogue, L Petty, T Valley, JP Mills, K Kaye Open Forum Infectious Diseases 5 (Suppl 1), S453, 2018 | | 2018 |
| 1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the … JM Pogue, RN Jones, JS Bradley, D Andes, SM Bhavnani, M Dudley, ... Open Forum Infectious Diseases 6 (Supplement_2), S559-S559, 2019 | 1 | 2019 |
| 1562. Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity. T Simpson, S Shah, JM Pogue, J Wu Open Forum Infectious Diseases 6, 2019 | 5 | 2019 |
| 1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI). S Alosaimy, SCJ Jorgensen, A Lagnf, EJ Zasowski, TD Trinh, R Mynatt, ... Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance? TS Patel, V Marshall, KS Kaye, A Smith, C Young, P Lephart, JM Pogue Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 1764. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of Candida auris: The Michigan Experience BM Brennan, SE McNamara, E Stier, A Malani, JM Pogue, AM Ressler, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1595, 2023 | | 2023 |
| 1811. Minimizing Time to Optimal Therapy for Enterobacteriaceae Bloodstream Infections: Is Organism Identification Enough? LN Cwengros, RP Mynatt, TT Timbrook, JM Pogue Open Forum Infectious Diseases 5 (Suppl 1), S514, 2018 | | 2018 |
| 2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial … C Cooper, O Henig, K Kaye, N Hussain, Z Hussain, K Deeds, H Salimnia, ... Open Forum Infectious Diseases 5 (Suppl 1), S606, 2018 | | 2018 |
| 2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR … S Shah, G Haidar, KM Squires, EG Kline, JM Pogue, EK McCreary, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1808, 2023 | | 2023 |
| 2193. Factors Impacting the Duration of Antimicrobial Therapy for Community-Acquired Pneumonia. A Sandhu, E Goldman, J Polistico, S Polistico, A Oudeif, A Aranha, ... Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 2222. Impact of Empiric Aminoglycoside Usage on Outcomes in Bacterial Pneumonia. O Albin, TS Patel, O Henig, T Valley, JM Pogue, LA Petty, J Mills, ... Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram … KN Tran, R Mynatt, KS Kaye, JM Pogue Open Forum Infectious Diseases 6, 2019 | | 2019 |
| 2250. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. SCJ Jorgensen, TD Trinh, EJ Zasowski, S Alosaimy, S Melvin, S Bhatia, ... Open Forum Infectious Diseases 6, 2019 | 5 | 2019 |
